Nuon Therapeutics Inc. Names Michael M. Kitt, M.D., Chief Medical Officer

SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the appointment of Michael M. Kitt, M.D., to the position of Chief Medical Officer.

“Dr. Kitt is an experienced clinician who will lead Nuon’s clinical development programs in the area of autoimmune disease. Michael has been responsible for the successful completion of clinical trials in a variety of clinical indications and will be able to apply his extensive knowledge and depth of expertise to our programs,” said Rodney Pearlman, Ph.D., President and CEO of Nuon Therapeutics. “Michael has functional experience in multiple areas involved in drug development and has a keen grasp of the issues and challenges in taking a drug through the clinical development process. He also has considerable regulatory experience, which will be invaluable as we advance our lead compound, tranilast, into clinical trials.”

Dr. Kitt was most recently Senior Vice President, Development at Theravance, Inc., where he had responsibilities for Clinical Research, Medical Affairs, Biostatistics & Data Management, Regulatory Affairs, Preclinical, Safety & Toxicology and Project Management. He was involved in filing numerous INDs, taking one compound through to NDA stage. Prior to this, Dr. Kitt was Vice President of Clinical Research at COR Therapeutics, where he was responsible for the clinical program for Integrilin, which was approved for two indications in both the U.S. and Europe. Previously, he was Sr. Vice President for Clinical Research at Sterling-Winthrop, where he was involved in the clinical development of a number of novel compounds. Prior to that, at the Upjohn Company, he held numerous positions in the clinical field, including several years in the European Clinical Research Office in Belgium. Dr. Kitt has a B.S. in Chemistry from the Polytechnic University in New York and an M.D. from NYU.

About Nuon Therapeutics, Inc.

Nuon Therapeutics, Inc. is a clinical stage biotechnology company that develops innovative small molecule drugs that address critical, unmet needs in autoimmune disease and pain. Nuon Therapeutics’ initial programs, based on an exclusive license to technology developed by Imperial College London and Stanford University, are focused on developing tranilast to treat rheumatoid arthritis, multiple sclerosis and pain. The Company has raised a total of $32 million since 2007 from investors including Frazier Healthcare Ventures, Domain Associates, L.L.C., and GBS Venture Partners to support clinical development. Nuon Therapeutics, Inc. has its headquarters in San Mateo, CA and has a wholly-owned subsidiary, Nuon Therapeutics Pty. Ltd., in Australia.

For additional information, please visit: www.nuontherapeutics.com